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Abstract
Background and aims
Lactulose is a common food ingredient and widely used as a treatment for constipation or
hepatic encephalopathy and a substrate for hydrogen breath tests. Lactulose is fermented
by the colon microbiota resulting in the production of hydrogen (H2). H2 is a substrate for
enteropathogens including Salmonella Typhimurium (S. Typhimurium) and increased H2
production upon lactulose ingestion might favor the growth of H2-consuming enteropatho-
gens. We aimed to analyze effects of single-dose lactulose ingestion on the growth of intrin-
sic Escherichia coli (E. coli), which can be efficiently quantified by plating and which share
most metabolic requirements with S. Typhimurium.
Methods
32 healthy volunteers (18 females, 14 males) were recruited. Participants were randomized
for single-dose ingestion of 50 g lactulose or 50 g sucrose (controls). After ingestion, H2 in
expiratory air and symptoms were recorded. Stool samples were acquired at days -1, 1 and
14. We analyzed 16S microbiota composition and abundance and characteristics of E. coli
isolates.
Results
Lactulose ingestion resulted in diarrhea in 14/17 individuals. In 14/17 individuals, H2-levels
in expiratory air increased by�20 ppm within 3 hours after lactulose challenge. H2-levels
correlated with the number of defecations within 6 hours. E. coli was detectable in feces of
all subjects (2 x 102–109 CFU/g). However, the number of E. coli colony forming units (CFU)
on selective media did not differ between any time point before or after challenge with
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sucrose or lactulose. The microbiota composition also remained stable upon lactulose
exposure.
Conclusion
Ingestion of a single dose of 50 g lactulose does not significantly alter E. coli density in stool
samples of healthy volunteers. 50 g lactulose therefore seems unlikely to sufficiently alter
growth conditions in the intestine for a significant predisposition to infection with H2-consum-
ing enteropathogens such as S. Typhimurium (www.clinicaltrials.gov NCT02397512).
Introduction
Humans coexist with trillions of microbes on their body surfaces, collectively referred to as
microbiota. One of the key benefits these microbes confer to their host is colonization resis-
tance (CR), i.e. protection against invasion and infection by pathogens. It is conceivable that
during gut colonization, the pathogen has to compete with the resident intestinal microbiota
for nutrients and binding sites (nutrient-niche hypothesis) [1, 2]. Yet, the mechanistic details
underlying the protective effect by the microbiota have not been fully elucidated.
Several perturbations can disrupt colonization resistance. Antibiotic treatment can disturb
the intestinal microbiota, predisposing the host to infections with enteric pathogens including
Salmonella Typhimurium (S. Typhimurium) and Clostridium difficile in humans [3] and in a
murine model [1, 4, 5]. Likewise, according to the nutrient-niche hypothesis, providing the
ecosystem with an additional nutrient should also open new niches, which might reduce colo-
nization resistance for certain pathogens. Effects of long-term and short-term (< 1 day) per-
turbations might thereby differ since long-lasting interventions will trigger complex secondary
responses of the gut ecosystem.
The disaccharide lactulose is used as a food ingredient (named galacto-fructose) [6, 7] and
as a prescription or over-the-counter medication for constipation [8] or hepatic encephalopa-
thy in individuals with liver cirrhosis [9]. The lactulose breath test uses lactulose to diagnose
small intestinal bacterial overgrowth [10]. As lactulose cannot be absorbed during the passage
through the host’s small intestine [11], it reaches the large intestine where it enriches the nutri-
ent pool available to the gut microbiota. After arrival, lactulose is fermented by certain gut
microbiota members resulting in the production of short chain fatty acids (SCFA), hydrogen
(H2) and methane [12, 13]. The production of these compounds explains the laxative proper-
ties and also the side effects (abdominal pain and bloating) of this drug. Based on these obser-
vations, it seems likely that the intake of lactulose might significantly alter nutrient availability
in the colon and thereby change the colonic microbiota composition. Effects of short-term lac-
tulose exposure on the gut microbiota have been insufficiently studied.
We hypothesized that lactulose may also promote gut luminal growth of Enterobacteriaceae
like S. Typhimurium or Escherichia coli (E. coli). E. coli shares most metabolic requirements of
S. Typhimurium and growth of E. coli in stool samples is considered a surrogate for favorable
growth conditions of enteropathogens such as S. Typhimurium [14]. In contrast to S. Typhi-
murium, E. coli can grow on lactulose, i.e. by taking up and degrading this disaccharide. How-
ever, E. coli might also benefit directly or indirectly from the sugar monomers galactose and
fructose, which are released upon degradation of lactulose by certain members of the gut
microbiota [15, 16] or by fermentation products like H2. H2 can serve as an electron donor for
S. Typhimurium and other Enterobacteriaceae [17–21]. Data in our murine model of S.
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Typhimurium colitis demonstrated significant attenuation of a S. Typhimurium mutant defi-
cient in H2-metabolism during initial stages of infection [18]. H2 therefore constitutes a critical
metabolic intermediate exploited by S. Typhimurium for efficient colonization of the large
intestine [18].
These data from animal experiments raise the possibility that lactulose exposure might pro-
mote growth of intestinal pathogens also in humans. Since lactulose is frequently used in medi-
cal practice for instance for patients with advanced liver disease (see above), such a finding
would have significant medical implications. However, the relevance of the mouse data has not
been validated in humans.
Our study aims to test the hypothesis that the intake of lactulose can promote gut luminal
growth of Enterobacteriaceae such as E. coli and S. Typhimurium. This effects might manifest
rapidly since previous studies demonstrated alterations in microbiota composition within 24
hours after dietary interventions [22–25]. A single lactulose dose will allow monitoring direct
effects of this intervention, avoiding the complexity of secondary physiological and microbio-
logical compensatory responses upon long-term exposure.
In this study, we assessed short-term effects of lactulose intake on human volunteers using
a single lactulose dose. We tested for preferential growth of Enterobacteriaceae (Enterobacter-
iaceae blooms) which would indicate increased risk for infection by Enterobacteriaceae in
healthy individuals and by extrapolation in patients.
Experimental procedures
Sample size calculation
To test the primary hypothesis of our study that lactulose exposure would increase growth of
E. coli (as a marker for Enterobacteriaceae) the following sample size calculation was per-
formed: To be clinically relevant, the difference in E. coli counts after lactulose exposure com-
pared to sucrose should be at least one order of magnitude. Bacteria concentrations were
estimated to be normally distributed. In a conservative calculation, we estimated a bacteria
concentration of 100’000 cfu/g with a standard deviation of 100’000 in the sucrose group and a
bacteria concentration of 1’000’000 cfu/g with a standard deviation of 1’000’000 in the lactu-
lose group. In a two-tailed unpaired analysis, a sample size of 30 individuals (15 in each group)
would be required to detect this difference with a power of 90% at a significance level of 0.05
(Mann-Whitney U test).
Study participants
For this study, 32 healthy volunteers were recruited via advertising. Exclusion criteria were a
history of intestinal surgery (except hernia repair, appendectomy or anorectal surgery), preg-
nancy, relevant gastrointestinal symptoms (i.e., symptoms that cannot be ignored), medical or
psychiatric conditions requiring ongoing management or intake of medication affecting gas-
trointestinal function (for instance laxatives, opioids, non-steroidal anti-inflammatory drugs,
proton pump inhibitors or antibiotics within the last 4 weeks). To ensure proper handling of
stool samples only employees of ETH Zurich or Zurich University, familiar with freezing and
storing samples at -80˚C were recruited. All participants provided written informed consent
and were compensated for their expenses. The first participant was included on the 30th of Jan-
uary 2015, the last participant was included into the study at the 14th of April 2015 and com-
pleted the study on 30th of April 2015. No follow up was performed (Fig 1).
Participants were screened during an interview and epidemiological data, information
regarding gastrointestinal function or symptoms, medical history, medication, gastrointestinal
function and life style (vegan, vegetarian or Western diet, sport [hours of exercise per week],
Microbiota stability upon lactulose challenge
PLOS ONE | https://doi.org/10.1371/journal.pone.0206214 October 25, 2018 3 / 25
alcohol consumption, smoking) were recorded (Table 1). Before the intervention day, partici-
pants fasted for 12h with only water allowed prior to the intervention.
Our study was approved by the Ethics committee of Zurich county (KEK-ZH 2014–0358)
and registered at clinicaltrials.gov (NCT02397512).
CONSORT 2010 Flow Diagram
Assessed for eligibility (n=32)
Excluded (n= 0)
¨ Not meeting inclusion criteria (n=0)
¨ Declined to participate (n=0)
¨ Other reasons (n=0)
Analysed (n=17)
¨ Excluded from analysis (give reasons) (n= 0)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=0)
Allocated to intervention (n=17)
¨ Received allocated intervention (n= 17 )
¨ Did not receive allocated intervention (give
reasons) (n=0)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=0)
Allocated to intervention (n=15)
¨ Received allocated intervention (n=15)
¨ Did not receive allocated intervention (give 
reasons) (n= 0 )
Analysed (n=15)
¨ Excluded from analysis (give reasons) (n= 0
)
Allocation
Analysis
Follow-Up
Randomized (n=32)
Enrollment
Fig 1. Consort flow chart.
https://doi.org/10.1371/journal.pone.0206214.g001
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Study design
The participants were randomly assigned to two groups (http://www.graphpad.com/
quickcalcs/randomize1.cfm) using the sealed envelope method and treated in a double blinded
fashion. The control group (n = 15) received a sham treatment of 50 g sucrose (Migros,
Zurich) dissolved in 200 ml water. The intervention group (n = 17) consumed a drink contain-
ing 50 g lactulose (Legendal 12g, Zambon, the Netherlands) dissolved in 200 ml water (Fig 2).
H2 levels in parts per million (ppm) in expiratory air of participants were measured at 0 min
(baseline), 15 min, 30 min, 60 min, 90 min, 120 min, and 180 min after the consumption of
the respective sugar solution using the HydroCheck breath measuring device (Neomed Medi-
zintechnik GmbH U¨chtelhausen, Germany) (Fig 2). Methane content of expiratory air was
recorded using Breath Collection Kit (BreathTracker SC, QuinTron USA). Due to technical
issues, methane measurements could be performed only in the last 14 individuals included in
our study. At all time points participants were asked to evaluate the strength of nausea, bloat-
ing, pain, stool alterations and borborygmi (bowel sounds) using a 4-point scale (1—no symp-
toms, 2—light symptoms which can be ignored [i.e. will not be noticed if attention is shifted to
another topic], 3—marked symptoms which cannot be ignored [i.e. will typically be noticed
even if individual actively shifts attention to other topics] but would not affect daily activity
and 4—severe symptoms affecting daily activities. An additional questionnaire recorded bowel
Table 1. Epidemiological and clinical characteristics of the study population. BSS: Bristol stool scale; IQR: inter-
quartile range.
Sucrose Lactulose
Number of participants 15 17
Age: median (IQR; range) 25 (23–28.5; 21–36) 24 (22–31; 21–47)
Gender: female n (%) 9 (60%) 9 (53%)
Stool frequency
every 2–3 days: n (%) 2 (13%) 3 (18%)
1x per day: n (%) 10 (67%) 12 (70%)
2-3x per day: n (%) 3 (20%) 2 (12%)
Stool consistency (BSS)
median (IQR; range) 4 (3–4; 3–7) 4 (3–4; 3–4)
Diet
Western diet 15 (100%) 15 (88%)
Vegetarian diet - 2 (12%)
Non-smokers: n (%) 15 (100%) 17 (100%)a
Physical exercise per week (hours)
median (IQR; range)
4 (3–5.5; 2–8) 3 (2–5; 0–12)
Medication: Yes n (%) 8 (53%)b 7 (41%)c
Ethnicity
Caucasian: n (%) 14 (93%) 14 (82%)
Non-Caucasian: n (%) 1 (7%)d 3 (18%)e,f,g
a Minimal nicotine consumption in one person (3–4 cigarettes/week)
b 3x hormonal contraception, 1x thyroid hormone replacement, 3x ibuprofen
c 3x hormonal contraception, 1each ibuprofen, paracetamol, thyroid hormone replacement
d born in Vietnam, living in Switzerland for 2 years
e parents from Sri Lanka, participant born in Switzerland
f born in Turkey, living in Switzerland for 4 years
g born in Cameroon, living in Switzerland for 3 years
https://doi.org/10.1371/journal.pone.0206214.t001
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consistency (maximum Bristol stool scale, BSS) and frequency of bowel movements during 6
hours after the consumption of the respective sugar solution.
To assess effects on the resident gut microbiota, fecal samples were collected one day before,
one day after, and two weeks after lactulose or sucrose exposure (Fig 2). Half of the fecal sam-
ple was stored in a test tube containing trypticase soy broth (Oxoid/ Thermo Fisher Diagnos-
tics AG, Pratteln, Switzerland) with 15% (w/v) glycerol (Sigma-Aldrich, Buchs, Switzerland)
[26]. This sample was used for the analysis of the colony forming units (CFU) per gram feces
and the isolation of single bacterial strains. The other half of the fecal sample was stored in a
test tube without any supplements and used for the analysis of microbiota composition.
Within one hour after collection, samples were delivered by the participants and stored in a
-80˚C freezer provided by the investigators. To ensure proper handling of samples only indi-
viduals familiar with handling of -80˚C freezers had been recruited (see inclusion criteria
above) and importance of rapid sample transfer was emphasized to all individuals. Timely
transfer of the fecal sample to the freezer within 30–60 min was confirmed by questionnaires
to participants.
Microbiota quantification and isolation of Enterobacteriaceae by agar
plating
Fecal samples were transferred to Eppendorf tubes containing 500 μl of phosphate buffered
saline (PBS) with tergitol (Sigma-Aldrich) and a sterile metal ball, weighed, and homogenized
(1 min at 25 Hz, using a TissueLyser (Qiagen, Hombrechtikon, Switzerland). Differential plat-
ing on MacConkey agar plates (Oxoid) without any antibiotics allowed identification of
32 healthy participants
day -1 day 0 day 1 day 14
Feces seceFseceF
H2 in breath
(baseline level, 15 min, 30 min, 60 min, 90 min, 120 min, 180 min)
Double-blinded
Lactulose breath test
control group: 50 g sucrose
test group: 50 g lactulose
Isolation of indicator strains & analysis of microbial composition
Fig 2. Overview of the design of our study. 32 healthy participants were randomly assigned to either the control group (sucrose) or to the experimental
group (lactulose). Fecal samples were collected one day before treatment, one day after treatment and two weeks after treatment for further microbial
analysis. On the day of treatment, hydrogen levels were measured in expiratory air at the indicated time points.
https://doi.org/10.1371/journal.pone.0206214.g002
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bacterial population size (CFU; i.e. E. coli, Salmonella spp. and other Enterobacteriaceae)
within the individual samples. In an attempt to capture the enterobacteriaceal diversity, several
morphologically different colonies from each time point were picked and restreaked three
times on new MacConkey agar plates. After restreaking, pure single colonies were picked and
cultured in lysogeny broth (LB) for 10-12h at 37˚C shaking (160 rpm). Bacterial cultures were
stocked in peptone glycerol broth (peptone: Oxoid, glycerol: Sigma-Aldrich), shock frozen and
stored at -80˚C.
Antibiotic susceptibility testing
Test antibiotics were chosen according to known genetic determinants of resistance [27]. Test
tubes containing 2 ml LB media were inoculated with the isolated bacterial strains and incu-
bated for 5h at 37˚C shaking (160 rpm). Optical density (OD) 600 was measured and a fraction
of the culture was used to inoculate new test tubes containing 2 ml LB media to obtain a final
OD 600 of approximately 0.02. Liquid cultures were diluted 1:10 in sterile ddH2O and streaked
with a cotton swab three times with 45˚ shifts on Mueller-Hinton agar to obtain a bacterial
lawn of a density according to British Society for Antimicrobial Chemotherapy (BSAC) stan-
dards [28]. Antibiotic discs were placed on the agar using sterile tweezers, followed by incuba-
tion at 37˚C for 18-20h. The diameter of the zone of inhibition was measured for each
antibiotic and bacterial strains were classified as susceptible, intermediate, and resistant
according to the Clinical and Laboratory Standards Institute (CLSI) [29].
16S rRNA gene analysis of isolated Enterobacteriaceae strains
For each bacterial strain, 50 μl of an overnight culture were centrifuged (5min, 8000 rpm), sus-
pended in 100 μl sterile H2O and incubated at 99˚C for 3 min. Genomic DNA was collected
from supernatant after centrifugation (3min, 8000 rpm). 8 μl DNA was amplified by PCR in a
100 μl reaction mixture containing 10 μl buffer (5 PRIME PCR master kit), 5 U Taq polymer-
ase (5 PRIME PCR master kit), 8 μl 2.5 mM dNTPs, 53 μl ddH2O and 10 μl of each forward
primer (fD1: 5'-AGAGTTTGATCCTGGCTCAG-3') [30] and reverse primer (rP1: 5'-ACGG
TTACCTTGTTAGCACTT-3') [31] diluted 1:10 in ddH2O (final primer concentration 1 μM).
The amplification program consisted of an initial denaturation step of 5 min at 94˚C; followed
by 35 cycles of 1 min at 94˚C, 1 min at 43˚C, and 2 min at 72˚C; and a final extension of 7 min
at 72˚C. A negative control was included in each batch of PCR reactions. Correct PCR product
size was confirmed using agarose gel electrophoresis and ethidium bromide staining, DNA
fragments were excised under UV light and extracted using the Wizard SV Gel and PCR
Clean-Up System (Promega, Du¨bendorf, Switzerland).
Excised DNA fragments were sent for sequencing at Microsynth AG Balgach, Switzerland.
The sequences were annotated by the basic local alignment search tool (BLAST) [32] for taxo-
nomical identification. Entries were sorted by "Max score" and the top record used to annotate
the genus and, if reliable, also the species classification for each bacterial strain. The sequence
alignment tool MUSCLE [33] and SplitsTree 4.13 [34] were used to construct phylogenetic
trees based on the BLAST annotations.
DNA extraction for 16S gene-based microbiota composition analysis
DNA was extracted using the QIAamp Stool Mini Kit (Qiagen) with the following changes in
the disruption and homogenization steps: 700μl of Buffer ASL, 2 spoons of small glass beads
(0.1mm; Bio Spec products) and 1 spoon of large glass beads (0.5–0.75mm; Schieritz&Hauen-
stein, Laufen, Switzerland) were added to each stool sample. The samples were mixed using
the TissueLyser (Qiagen) (3 min, 30Hz) and heated for 5 min at 95˚C. Next, samples were
Microbiota stability upon lactulose challenge
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again mixed using the TissueLyser (3 min, 30Hz), centrifuged at full speed for 1 min and the
supernatants were transferred to a new 2 ml microcentrifuge tube. The pellet was suspended
in 200 μl of Lysis Buffer (20mg/ml lysozyme (Sigma-Aldrich); 20mM Tris•HCl, pH 8.0; 2mM
EDTA; 1.2% Triton) and incubated at 37˚C for 30 min. Afterwards, 500 μl of Buffer ASL were
added to each sample followed by mixing using the TissueLyser (3min, 30Hz) and heating the
suspension for 5 min at 95˚C. All samples were mixed again using the TissueLyser (3 min,
30Hz) and centrifuged at full speed for 1 min. The supernatants were transferred to the same 2
ml tube than used before. Half of an InhibitEX tablet (provided in Kit) was added to each sam-
ple and tubes were vortexed immediately until the tablet was completely suspended. Next,
samples were incubated for 1 min at room temperature, centrifuged at full speed for 3 min and
supernatants were transferred into a new 1.5 ml microcentrifuge tube. The samples were again
centrifuged at full speed for 3 min. Meanwhile, 35 μl of proteinase K (provided in Kit) was
added to a new 2 ml tube and supernatants from the previous centrifugation step were trans-
ferred to the 2 ml tube containing the proteinase K. 200 μl of Buffer AL were added and sam-
ples were vortexed for 15 sec and incubated at 70˚C for 10 min. The next steps were performed
according to the manual instructions. The final elution step was performed using 100 μl Buffer
AE (pre-heated to 70˚C) added to the membrane, then samples were incubated for 1 min at
room temperature and centrifuged at full speed for 1 min to elute DNA.
Library preparation and sequencing for microbiota composition analysis
The 16S rRNA gene libraries were produced using the NEXTflex1 16S V4 Amplicon-Seq Kit
2.0 (Barcodes 1–96; Bioo Scientific, Austin, Texas, USA). The input concentration of genomic
DNA was adjusted to 30 ng/μl for each PCR reaction. The library preparation was performed
following the manufacturer’s instructions with the differences that the reaction volume was
reduced to 25 μl and a modified primer pair was used for the first PCR reaction (final primer
concentrations 0.5 μM). Instead of the original primer pair 515f-806r, the degenerative primer
515F (50-GTGYCAGCMGCCGCGGTAA-30) and 806rB (5’-GGACTACNVGGGTWTCTAAT-
3’), as described in [35, 36] were used. The first PCR reaction was performed using Q5 High-
Fidelity DNA Polymerase (BioConcept, NEB, Allschwil, Switzerland) under the following
cycling conditions: 1) initial denaturation: 95˚C for 4 min; 2) denaturation: 95˚C for 30 sec; 3)
annealing: 56˚C for 30 sec; 4) extension: 72˚C for 90 sec; 5) final extension: 72˚C for 4 min.
Cycles 2–4 were repeated 8 times. A negative control was included in each batch of PCR reac-
tions, which showed no signs of amplification. After each reaction, the PCR products were
cleaned up using AMPure XP magnetic beads (Beckman Coulter SA, Nyon, Switzerland). The
clean PCR products were eluted in 20 μl of resuspension buffer and used in a second PCR reac-
tion for producing multiplexed samples, respectively. The quantity of the amplicons was mea-
sured by a Qubit 3.0 fluorometer (Thermo Fisher Scientific). The quality of the amplicons was
evaluated using a Fragment Analyzer (Advanced Analytical, Ankeny, IA, USA). The length of
the barcoded amplicons was approximately 450 bp. The amplicons were pooled at equimolar
concentrations and diluted to a final concentration of 60 ng DNA per 20 μl before loading on
the Illumina MiSeq platform. Sequencing was performed at 2 x 250 bp read length at the Func-
tional Genomics Center Zurich. All sequences obtained during this project have been depos-
ited at the European Nucleotide Archive under the accession number: PRJEB28417
Microbiota composition analysis
Initial analyses were performed using USEARCH (version 9.1.13) [37] using custom scripts
that performed the following steps: paired reads were merged and quality-filtered using the
fastq_mergepairs command with default settings. Merged reads were filtered using the
Microbiota stability upon lactulose challenge
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fastq_filter command (-fastq_maxee 1.0) and only merged reads with perfect primer matches
and a minimum length of 100 bp were selected. Sequences were de-replicated using the fas-
tx_uniques and clustered into operational taxonomic units (OTUs) at 97% with chimera
removal using the cluster_otus command (-minsize 2). OTU abundances for each sample were
quantified using the usearch_global command (-strand both; -id 0.97). Taxonomic annotation
was performed by matching OTU sequences against the SILVA database (version 128) using
the usearch_global command (-id 0.90; -maxaccepts 20; -maxrejects 500; -strand both;
-top_hits_only).
Further analyses were performed in RStudio (version 1.0.143 based on [R] version 3.3.3)
using the libraries vegan [38] and ggplot2 [39]. Read counts were rarefied using the function
rrarefy to 19’000 reads per sample based on the sample with the lowest number of sequencing
reads after excluding five samples that had too few reads. Shannon’s diversity index for each
sample was calculated using the diversity function. For performing a Principal Coordinate
Analysis and for calculating intra-individual dissimilarity (grouped by time point or individ-
ual), Bray-Curtis distances were computed between pairs of samples using the vegdist
function.
Statistical analysis
Patient data with time curves for symptoms after lactulose/ sucrose exposure were analyzed
using two-way repeated measures ANOVA (GraphPad Prism Version 7.02 La Jolla, CA, USA,
www.graphpad.com). Correlation analysis for symptoms, hydrogen levels and Enterobacteria-
ceae counts was performed using Spearman R correlation of GraphPad Prism. Group compar-
isons for Enterobacteriaceae counts was done using the Mann-Whitney U test of GraphPad
Prism. The sample size calculation was performed using G�Power Version 3.1.9.2 [40]. A p-
value of less than 0.05 was considered significant.
Microbiota composition analysis was done using USEARCH (version 9.1.13) [37] and R
Studio (version 1.0.143 based on [R] version 3.3.3) with the libraries vegan [38] and ggplot2
[39] as described above. Significant differences between time points for each treatment group
as well as phylum-level taxonomic abundances were calculated by paired Wilcoxon tests with
FDR correction (0.05) for multiple testing. We also determined intra-individual dissimilarity
using the Bray-Curtis distance and compared different sampling time points by paired Wil-
coxon tests. For this analysis only individuals with samples from all three time points were
included (n = 14 for sucrose, n = 13 for lactulose). To assess sources of variation in our data
set, we tested the relative contribution of individuality and treatment to the overall variation of
microbial compositions by permutational MANOVA (Permutations = 999).
Results
Study population
Our study recruited 32 healthy volunteers (Fig 1), 18 out of 32 (56%) female of young age
(median 25, IQR: 22.75–30, Table 1). All individuals had normal bowel habits (frequency of
bowel movements every 2–3 days to 2–3 times per day, median BSS 4), were non-smokers and
most individuals followed a Western diet with regular physical activity. Medical history did
not reveal relevant medical conditions or gastrointestinal complaints; medication included
only analgetics, thyroid hormone replacements and hormonal contraception (Table 1). Thus,
we recruited a homogenous healthy study population.
Microbiota stability upon lactulose challenge
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Symptoms upon sucrose and lactulose ingestion
Individuals were randomized with 17 individuals in the intervention group with lactulose
ingestion and 15 individuals in the control group with sucrose ingestion, respectively (Fig 2).
Following ingestion of the respective disaccharide, 14/17 (82%) of individuals in the lactulose
group but only 3/15 (20%) of individuals in the control group reported physical symptoms.
Within three hour of observation on a five-point scale, scores for bloating, diarrhea, borbo-
rygmi (bowel sounds) and abdominal pain of the lactulose group were significantly higher
compared to the sucrose group (bloating: median 2 [range 1–4] vs. 1 [1–2], p = 0.0006; diar-
rhea: median 1 [range 1–5] vs. 1 [1–1], p = 0.0128; borborygmi: median 2 [range 1–4] vs. 1 [1–
2], p = 0.0005; abdominal pain: median 1 [range 1–3] vs. 1 [1–2], p = 0.0163; Fig 3, S1 Table).
On separate questioning, 13 out of 17 individuals reported diarrhea (defined as�3 bowel
movements within 6 hours after lactulose intake); diarrhea was accompanied by loose stool
consistency (Bristol stool scale, BSS�5 in all individuals with diarrhea). 5 of those reported
�4 bowel movements with BSS 7. The remaining 4 out of 17 individuals did not respond to
lactulose treatment with no defecation during 6 hours in 3 participants and 1 defecation BSS 5
in the remaining participant. No diarrhea was observed in the control (sucrose).
After lactulose exposure, H2 levels in expiratory air gradually increased for the next 90 min
and remained at significantly higher level with lactulose compared to sucrose (p<0.001) until
the end of the observation period (180 min, Fig 4). H2 levels varied widely (0–146 ppm); for
three individuals of the lactulose intervention group, H2 levels in expiratory air never increased
for more than 20 ppm over baseline; these individuals are by definition H2 non-producers
[10].
For 14 out of 32 individuals (5 in the sucrose group, 9 in the lactulose group) methane
(CH4) measurements were also taken (Fig 4B); for technical reasons, only the last 14 individu-
als included into our study could be tested. However, only a single individual had increased
CH4 levels at baseline (15 ppm) and for no individual CH4 levels exceeded 10 ppm over base-
line. For the three H2 non-producers no CH4 measurements were available.
H2 levels in expiratory air correlated with number of defecations (p = 0.024, Fig 4C); corre-
lation analysis with stool consistency (BSS) revealed a non-significant trend (p = 0.052, Fig
4D), suggesting that the intestinal response to lactulose was associated with H2 production.
Bacterial growth in stool samples of lactulose and sucrose treated subjects
We tested whether lactulose ingestion and exposure of the intestine to excess H2 increases lev-
els of E. coli and related Enterobacteriaceae in stool samples. Consistency of collected stool
samples (as judged by in inspection of collected material) was similar at all time points (day -1,
day 1 and day 14), arguing against significant confounding by sample dilution. Stool samples
were plated on selective media to quantify E. coli one day before (baseline), one day after, and
two weeks after disaccharide exposure (Fig 5). At all time points, no difference in bacterial
numbers could be detected (Fig 5A–5C). Variation within the two groups was high, with bacte-
rial densities ranging from 3 x 102 to 109 colony forming units (CFU) per g fecal sample in the
control group and 2 x 102 to 8 x 108 CFU per g in the lactulose group (Fig 5A–5C).
CFU counts remained stable over time and no difference for time points could be detected
in a paired analysis (p>0.05 for all comparisons, Wilcoxon matched pairs signed-rank test).
We found significant correlations of the number of CFUs at baseline, day 1 and day 14 in the
group with lactulose treatment (Fig 5D–5F), indicating stability of E. coli population size over
time and upon lactulose perturbation.
Considering the H2 metabolism in E. coli and other organisms (e.g. S. Typhimurium, Yersi-
nia, Campylobacter, Shigella [17–21] our data argue against a pronounced effect of increased
Microbiota stability upon lactulose challenge
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H2 levels on the growth of potential invading enteropathogens. In line with this interpretation,
the number of CFU at the day after lactulose exposure (or the ratio of CFU between time
points) did not correlate with maximum H2 levels in expiratory air at the intervention day
(Figure A in S1 Fig).
Number of CFUs or ratios of CFUs between days also did not correlate with number of def-
ecations after lactulose exposure (Figure B in S1 Fig). We noted a positive correlation between
CFU and stool consistency (BSS) and the ratio of CFUs on day -1: day 1 in the control group
but not in the lactulose group (Figure C in S1 Fig).
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No Salmonella enterica colonies were detected in any of the stool samples, as judged from
the absence of color-less colonies on the MacConkey agar plates and 16S sequencing in ambig-
uous cases.
Phylogenetic analysis of stool isolates
To confirm species affiliation of isolated Enterobacteriaceae, bacterial strains from 30 partici-
pants at one day after treatment were analyzed by sequencing the 16S rRNA gene. Sequences
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were classified using the basic local alignment search tool (BLAST). All bacteria isolated from
MacConkey agar were found to belong to the family of Enterobacteriaceae with a large cluster
of 20 E. coli related species (20 E. coli, 5 E. coli/ Shigella) and a distantly related cluster of 2
Klebsiella, 2 Enterobacter and 1 Citrobacter species (Fig 6).
Antibiotic resistance
Annotated human bacterial isolates were tested for resistance against different antibiotics.
Seven antibiotics (imipenem, cefepime, gentamicin, kanamycin, ciprofloxacin, and trimetho-
prim/ sulfamethoxazole) from 5 classes (carbapenems, cephalosporins, aminoglycosides, fluo-
roquinolone and folic acid synthesis inhibitors) were chosen according to known genetic
determinants of resistance in Enterobacteriaceae to evaluate resistance status in environmental
settings [27].
Fig 5. E. coli counts in stool samples at different time points. (A-C) Stool samples were plated on selective agar without antibiotics to quantify E. coli counts
(CFU). ns = not significant; Mann-Whitney U test. (D-F) Correlations of E. coli counts within the feces collected at different time points. ns: not significant;
�p< 0.05 = significant; ��p< 0.01; ����p< 0.001; r: Spearman R correlation coefficient. Dashed lines = detection limit.
https://doi.org/10.1371/journal.pone.0206214.g005
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Fig 6. Phylogenetic tree of Enterobacteriaceae strains isolated one day after treatment. Tree showing the
relatedness between bacterial strains (n = 30) isolated from participant samples one day after treatment with sucrose
(grey) or lactulose (orange). 16S rRNA sequences were annotated by BLAST and aligned using MUSCLE and
SplitsTree. Escherichia/Shigella thereby indicates a strain with a sequence compatible with both, E. coli and Shigella.
Horizontal lines indicate nucleotide substitutions per site. Please note that E. coli and Shigella are extremely closely
related. Thus, the detection of Escherichia/Shigella-like sequences does not imply that Shigella spp. were present in the
stools of any of the participants.
https://doi.org/10.1371/journal.pone.0206214.g006
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All bacterial strains tested were susceptible to imipenem, cefepime, and kanamycin (S2 Table).
Bacterial resistance against ampicillin was common (11 out of 30 strains, 37%) followed by sulfa-
methoxazole/trimethoprim (7 out of 30 strains, 23%), ciprofloxacin (2 out of 30 strains, 7%) and
gentamicin (1 out of 30 strains, 3%). Five bacterial strains were resistant to two or more antibiotics
(S2 Table). No extended spectrum beta-lactamase producing strains were identified.
Stability of microbiota upon lactulose exposure
We used 16S rRNA gene sequencing to analyze the taxonomic composition of the intestinal
microbiota after lactulose challenge. Overall, we observed no significant difference in bacterial
diversity between lactulose and sucrose treated individuals at day 1 and day 14 compared to
pre-treatment conditions (Fig 7A). The microbiota composition was also highly similar
between lactulose and sucrose treatment. An example for phylum level compositions is pro-
vided in Fig 7B. The mean relative abundance of Enterobacteriaceae was 0.4% (interquartile
range 0.07% - 0.6%) of all intestinal bacteria detected by 16S sequencing. No significant alter-
ation in the relative abundance of the family Enterobacteriaceae and genus Escherichia-Shigella
(represented by a single OTU with a 100% sequence match to E. coli) was detected neither
within nor between treatment groups (false discovery rate (FDR)-corrected Wilcoxon tests)
and sampling time points within treatments (paired FDR-corrected Wilcoxon tests, S2 Fig).
We observed intra-individual shifts in the dissimilarity of microbial composition between
the different sampling time points (days -1, 1, 14). Nevertheless, the shifts were similar in size
for lactulose and sucrose treated individuals. Furthermore, we did not observe any clustering
of samples by treatment (principal coordinate (PCo); analysis Fig 7C). Similarly, we detected
no significant intra-individual dissimilarity changes before and after lactulose/ sucrose inges-
tion (Fig 7D). Additionally, there was no correlation between intra-individual dissimilarity
(i.e. dissimilarity between time points) and BSS or H2 levels (Fig 7E).
Given the absence of a strong treatment-related effect on microbial composition, we sought
to assess the sources of variation in our data set. To this end, we tested the relative contribution
of individuality and treatment to the overall variation of microbial compositions (permuta-
tional MANOVA). For both treatments, we found individual variations but not treatment to
explain the vast majority of the variation (effect of individuals: sucrose group—R2: 0.77,
p = 0.001; lactulose group—R2: 0.82, p = 0.001; effect of treatment: sucrose group–R2: 0.01 n.s.;
lactulose group–R2: 0.007, n.s.).
Discussion
We performed a placebo controlled randomized controlled study to test effects of a single dose
lactulose challenge on gastrointestinal microbiota composition and wellbeing in a homoge-
nous group of young healthy individuals. The following key observations were made: i) Lactu-
lose caused an increase in H2 levels in expiratory air and diarrhea in the vast majority of
individuals in the lactulose group. ii) In the lactulose group, H2 levels correlated with severity
of diarrhea (i.e. number of defecations). iii) Lactulose exposure did not increase the number of
CFU of E. coli in stool samples collected 1 day after exposure. iv) The microbiota composition
at that time point was also not significantly affected by single-dose lactulose challenge com-
pared to the sucrose control, indicating that individual day-to-day variations of the microbiota
are much stronger than the perturbation by a single 50 g lactulose ingestion.
Effectiveness of a single dose lactulose as a laxative
Usage of lactulose for the treatment of acute or chronic constipation is well established [41].
Recent randomized controlled trials used lactulose as a standard treatment for comparative
Microbiota stability upon lactulose challenge
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testing against sodium polyethylene glycol (PEG) [42, 43], sodium picosulfate [42] and Chi-
nese or Pakistan herbal medicine [44, 45]. Effects of PEG were stronger than lactulose in a
Cochrane meta-analysis [46] and PEG or liquid paraffin were more effective in children [47]
even though these differences are small and possibly not clinically relevant. Cost-effectiveness
of PEG and lactulose was virtually identical [48]. Interestingly, lactitol might be similarly effec-
tive, but more palatable with lesser side effects than lactulose [49].
We are not aware of a recent placebo-controlled randomized controlled trial for one-time
application of lactulose in young healthy individuals. Thus, our study provides valuable infor-
mation on the effectiveness of lactulose in healthy individuals. We observed diarrhea (i.e.�3
bowel movements in 6 hours) in 14 out of 17 (82%) of healthy participants ingesting lactulose
which was accompanied by at least moderate borborygmi, bloating, flatulence (14 out of 17,
82% for each symptom) and abdominal pain (8 out of 17, 47%).
Methane levels in expiratory air and H2 non-producers
A fraction of patients and healthy individuals contain a methanogenic organism such as
Methanobrevibacter smithii [50]. Hydrogenotrophic methanogens use 4 molecules of H2 and 1
molecule of carbon dioxide (CO2) to produce 1 molecule of methane (CH4) [51]. Due to this
additional metabolization step, the CH4 peak will be delayed and due to the 4:1 ratio of H2 and
CH4, the methane peak will be at a lower level compared to H2. Therefore, a cut-off of 10 ppm
for CH4 is suggested [10]. Furthermore, individuals with a methanogenic microbiota usually
have increased levels of CH4 even at baseline, but fail to produce measurable H2 upon appro-
priate testing [10]. In our analysis, methane measurements from only 14 individuals were
available and only for one person, methane levels exceeded the threshold of 10 ppm. Our study
included three H2 non-producers (18%) without any increase in H2 levels, well within the
expected range of 2–43% in healthy individuals or patients [52]. However, no methane mea-
surements for these individuals are available.
Correlation of symptoms with H2 levels
The healthy human intestine contains 30–200 ml (average 100 ml) gas, which mainly consists
of H2, CO2 and CH4 [10, 53]. Both, H2 and CH4 are exclusively produced by the bacterial
microbiota [50].
Our study found a significant association of peak H2-levels with severity of diarrhea upon
lactulose challenge in healthy individuals, arguing for a relationship between H2-production
and symptoms after lactulose challenge. The association of results of the lactulose breath test
with a diagnosis of irritable bowel syndrome (IBS) or IBS symptoms is controversial. A large
analysis failed to find differences in IBS patients vs. healthy controls [54]. However, the H2
response in the lactulose breath test was related to bloating in IBS patients [55–57]. Similarly, a
Fig 7. A single dose of lactulose (50 g) has no significant effect on fecal bacterial community structure a day or two weeks after treatment. (A)
Shannon diversity index shows no significant change (paired Wilcoxon test, P>0.05) one day or two weeks after treatment (sucrose n = 15, lactulose
n = 17) for each group. (B) Relative phylum abundance before (day -1) and after (day 1 and day 14) ingestion of sucrose (n = 15) or lactulose (n = 17).
Colors indicate bacterial phyla, none on which were significantly different between time points. (C) Principal coordinate (PCo) analysis of microbiota
composition with symbols and colors denoting sampling time point and treatment (sucrose, lactulose), respectively. The numbers denote the different
individuals with samples from all three time points. (D) Intra-individual dissimilarity (Bray-Curtis) of microbial composition in samples collected at
different sampling time points (day—1 to 1, day -1 to 14 and day 1 to 14) and treatments with sucrose (n = 14) and lactulose (n = 13). Only individuals
with samples from all three time points with a rarefaction cut-off of>19’000 were included in the intra-individual dissimilarity analysis (Bray-Curtis) of
the microbiota composition. No significant shifts in bacterial composition were detected between different time points (paired Wilcoxon test, p>0.05).
(E) Intra-individual dissimilarity (Bray-Curtis) of fecal microbial composition between the three sampling time points. The color key indicates the Bristol
stool scale (BSS) of the same day (i.e., day 0) and after the lactulose/ sucrose challenge. The grey dots show maximal hydrogen levels in parts per million
(ppm) following lactulose or sucrose ingestion.
https://doi.org/10.1371/journal.pone.0206214.g007
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recent study using a large cohort of Chinese IBS patients found both, high H2 levels (area
under the curve) in breath tests and visceral hypersensitivity to be risk factors for bloating and
borborygmi and overall symptom burden [58].
Methane data were available only for a subset of participants and no correlation with symp-
toms could be established. Previous studies confirmed an association of methane levels in expi-
ratory air with constipation [59, 60] and the severity of constipation correlated with methane
levels [59].
Stability of the microbiota upon single-dose lactulose challenge
In our study, no significant effects of a single dose of 50 g lactulose on microbiota composition
could be detected after 1 day or after 14 days (S2 Fig). The number of E. coli counts in our
study (104 to 108 cfu/g feces, Fig 5) and the mean relative abundance of Enterobacteriaceae
(0.4% of all intestinal bacteria detected by 16S sequencing) are well in line with numbers
described in the literature [61–65], indicating a normal intestinal microbiota before and after
lactulose challenge. Previous diet intervention studies showed that short-term macronutrient
shifts reversibly alter gut microbiota composition within 24 hours even though broad patterns
of microbiota composition similarities (enterotypes) remain stable [22–25]. Our PCo analysis
showed that lactulose challenge did not significantly alter the microbial composition since sim-
ilar patterns of small-scale shifting were observed for lactulose and sucrose, alike (day 1 and
day 14). Instead, our data argue for a stability of microbiota compositions with daily variations
dominating over changes due to a single intervention with 50 g lactulose, even though diarrhea
was observed in the majority of individuals. However, the data of this study provides no infor-
mation about short-term microbiota compositional changes immediately after lactulose chal-
lenge, nor about site-specific effects within the small intestine or the right-sided colon.
Effects of lactulose on the risks for intestinal infections
Prebiotics are food ingredients, which are neither digested nor degraded in the stomach or
small intestine, but fermented by the gut microbiota, leading to a selective stimulation of the
growth of certain intestinal bacteria and may thereby reap potential benefits for the host [66].
Lactulose, along with inulin and other oligosaccharides are considered prebiotics and Lactoba-
cillus and Bifidobacterium are considered significant target genera for the associated prebiotic
effects [66, 67].
Since over 50 years, lactulose has been considered the “bifidus factor”, increasing fecal Bifi-
dobacterium counts [68]. A number of subsequent studies have confirmed increased intestinal
content of Bifidobacterium [69–75] and Lactobacillus [69, 72] in human stool samples upon
lactulose exposure. Those studies relied on conventional microbiological techniques and did
not address the overall composition of the intestinal microbiota. Furthermore, in contrast to
our study, lower dosages of lactulose (5–20 g) and longer exposure times (4–8 weeks) were
used, potentially explaining differences to our results. In fact, effects on Bifidobacterium stool
densities were weaker and not significantly different from controls in an 8-day study [76].
However, short-term effects of lactulose on the intestinal microbiota have not been tested pre-
viously. No “bifidus factor” effects were observed in our study and differences in the time of
lactulose exposure might explain this discrepancy.
Fermentation of lactulose is not limited to Lactobacillus and Bifidobacterium. Glucosidases
and bacterial transporters for lactulose are abundant in a large number of intestinal bacteria
including Cronobacter, Enterococcus, Escherichia, Klebsiella, Pseudomonas, and Streptoccoccus
spp., which were able to grow on lactulose as the sole carbon source [13]. One recent study
addressed effects of feeding mice with lactulose for two weeks: The authors noted a decrease in
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pH and an increase in short chain fatty acids in the colon. In the same mice, an increase in Pro-
teobacteria and Actinobacteria including Bifidobacterium and a decrease in Firmicutes was
observed. An increase in Helicobacter and Akkermansia spp. content was interpreted to be sec-
ondary to increased mucin production. Similar to our study, no increase in E. coli content was
observed [77]. These changes were accompanied by an increase in Bifidobacterium, Lactobacil-
lus spp. and Enterobacteriaceae. In our study, we found a remarkable stability of the micro-
biota upon lactulose perturbation with 50 g lactulose resulting in diarrhea in >80% of
participants. In fact, day to day variation in the control group were as big as variations in the
experimental group and only approximately 3% of the variance can be explained by lactulose
treatment (not shown).
Effects of lactulose on growth of intestinal pathogens are controversial. In vitro co-cultures
of human intestinal Lactobacillus isolates with E. coli, Salmonella enteritidis or Vibrio cholerae,
demonstrated reduced growth of the enteric bacterial pathogens [78]. Case series also demon-
strated therapeutic effects of lactulose treatment for human carriers of non-typhoid Salmonel-
lae [79] and a temporary reduction of Shigella excretion in carriers [80]. Application of
lactulose was suggested to decrease the number of urinary tract infections [81]. However, in a
rat model of Salmonella enteritides infection, lactulose inhibited S. Typhimurium colonization,
but stimulated bacterial translocation and intestinal inflammation [82].
In our study, we were aiming to establish an experimental model for improved growth con-
ditions for Enterobacteriaceae. In vivo data from our group with a murine colitis model sug-
gested that the initial growth of S. Typhimurium within the first day depended on the presence
of enzymes enabling hydrogen utilization [18]. Better growth conditions for S. Typhimurium
would suggest a higher susceptibility for bacterial infections upon lactulose exposure. This
might be relevant for patients with liver cirrhosis who are highly susceptible to bacterial infec-
tions [83] and for whom lactulose remains the first-line drug for treatment and prevention of
hepatic encephalopathy [9].
In our study, we did not find an increase in E. coli levels one day after lactulose application
even though E. coli could potentially benefit from H2 produced upon lactulose ingestion. In
agreement with our results, no clinical data support an increased risk of Enterobacteriaceae
infections upon lactulose exposure. One reason for this could be that intrinsic E. coli are part
of metabolic networks in biofilms in the large intestine and might still depend on metabolic
contributions from other bacteria (according to the "Restaurant" hypothesis) [84], which limits
any stimulatory effects of H2 and further studies for the metabolization of lactulose in the
intestine are warranted.
In summary, exposure with a single lactulose dose leads to diarrhea in >80% of healthy
individuals but not to an increase in E. coli CFU and no microbiota shifts. A single lactulose
dose is therefore unlikely to significantly improve growth conditions of H2-consuming entero-
pathogens such as S. Typhimurium in the human gut.
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